As development proceeds from embryonic to fetal stages, cardiac energy demands increase 45 substantially, and oxidative phosphorylation of ADP to ATP in mitochondria becomes vital. 46
The adrenergic hormones, epinephrine (EPI) and norepinephrine (NE), are key mediators of 71 stress responses and sympathetic nervous system activities in adult mammals. NE, in 72 particular, is also essential for embryonic development. Targeted disruption of the gene 73 dopamine β-hydroxylase (Dbh), which codes for the enzyme that converts dopamine into NE, 74 led to a loss of NE and EPI, and embryonic lethality due to heart failure in mice (54). In 75 contrast, disruption of the subsequent enzymatic step catalyzed by phenylethanolamine n-76 methyltransferase (Pnmt) led to the loss of EPI without concomitant developmental phenotypes 77 (21). Thus, while EPI may contribute to adrenergic activity in the embryo, NE is clearly of critical 78 importance for heart development. 79
80
How NE influences heart development in utero is not fully understood. In Dbh -/-embryos signs 81 of cardiac distress begin to appear on embryonic day 10.5 (E10.5), and approximately 50% of 82 the Dbh -/-embryos die by E11.5 (54). Remarkably, the heart appears to develop and function 83 normally up to this point, but then deteriorates rapidly into heart failure within 24h of the first 84 signs, which include sluggish cardiac contractions, arrhythmia, and asynchrony as observed via 85 echocardiography in utero (43) . Recent work has shown that Dbh -/-hearts display significantly 86 delayed conduction speed across the atrioventricular junction relative to age-matched littermate 87 controls (1). These results suggest important adrenergic influences on the development of 88 cardiac structure and function, but do not fully explain how NE affects them. 89
90
At these early embryonic stages of development, there is no sympathetic innervation of the 91 heart, and the adrenal glands have not yet formed. Instead, NE is produced in the embryonic 92 heart itself, as well as outside of the heart in primordial sympathetic ganglia and brainstem 93 neurons (20) (21) (22) . With respect to heart function, NE appears to be acting primarily through β-94 adrenergic receptors since Dbh -/-embryos could be rescued by providing the β-agonist, 95 isoproterenol, in the maternal drinking water, whereas the α-agonist, l-phenylephrine, was 96 partially effective at rescuing the heart failure and lethality (55). These results established that 97 NE stimulates cardiovascular function during early embryonic development, but what are the 98 important physiological targets regulated by adrenergic stimulation in the embryonic heart? 99
100
To gain insight about adrenergic actions in cardiac development, we recently performed a 101
genome-wide expression screen of Dbh -/-and Dbh +/+ embryonic hearts. A key finding from this 102 screen demonstrated the largest category of differentially expressed genes (~31% of total) were 103 those involved in metabolism (43). In adult mammals, adrenergic hormones are known to have 104 profound and widespread influences on metabolism. In the liver, for example, β-adrenergic 105 stimulation inhibits glycolysis, promotes gluconeogenesis, and stimulates breakdown of 106 glycogen (6, 50). In cardiac and skeletal muscle, glycolysis and oxidative phosphorylation 107 (OXPHOS) are increased in response to β-adrenergic stimulation to produce more available 108 energy during stress. Free fatty acids are released from adipose tissue, and these serve as the 109 primary fuel source for cardiac metabolism in adult mammals, but prior to birth the heart 110 principally uses carbohydrates (8, 10, 17, 23, 26, 42, 48) . The shift from carbohydrate to lipid 111 metabolism in the heart mainly occurs at birth and is often referred to as the "fetal-shift" in 112 cardiac metabolism (19, 36, 37) . Surprisingly little, however, is known regarding adrenergic 113 influences on cardiac metabolism during the embryonic period. 114
115
There is compelling evidence indicating that aerobic metabolism in the mitochondria becomes 116 increasingly important as the heart transitions from embryonic to fetal stages of development. 117
For example, genetic mutations that decrease or disrupt OXPHOS often result in heart failure 118 and embryonic lethality (29, 34, 35) . Furthermore, mutations that disrupt mitochondrial structure 119 and function also interfered with cardiomyocyte differentiation and development (11, 12, 18, 58) , 120 and many of these ultimately succumbed to heart failure and embryonic lethality. Thus, there 121 appears to be an "embryonic-shift" from primarily anaerobic to aerobic metabolic mechanisms in 122 the heart during the embryonic-fetal transition period of development (2 dosing of maternal mice, drinking water was supplemented with ISO (0.02 mg/ml), l-169 phenylephrine (0.02 mg/ml), or timolol (1 mg/ml) beginning at E8.5, as previously described (49, 170 55). Vitamin C was added to the control and drug-containing drinking water bottles at a 171 concentration of 2 mg/ml to help minimize oxidation of the drugs (55). 172
173

Embryonic Tissue Collections 174
All embryos used in this study appeared healthy and viable at the time of isolation as judged by 175 their size (crown-rump lengths), color, texture, morphology, and overall appearance. 176
Microscopic examination confirmed a beating heart and bright red blood coursing through the 177 embryonic circulation. Unhealthy and dead embryos were discarded. From the living 178 specimens collected, no apparent differences were observed between adrenergic-deficient and 179 control embryos based on these gross examinations at the time of isolation. Upon isolation, the 180 heads were removed and used for genotyping. For RNA and biochemical assays, hearts or 181 trunks were flash-frozen in liquid nitrogen and stored at -80ºC. 182
183
Reagents 184
Flash-frozen embryos were homogenized for 1 min, and then centrifuged at 12,000 g for 1 min. 211
The supernatant was removed, and 2 µL was used to measure glucose concentrations using a 212
WaveSense Presto blood glucose (AgaMatrix) monitoring system (15). Samples were 213 compared to a standard curve of known D-glucose concentrations and normalized to total 214 protein concentrations. Measurements were done in triplicate. 215
216
Glycogen Measurements 217
Flash-frozen embryos were homogenized for 30 sec in 1 M potassium hydroxide solution, and 218 then incubated at 37ºC for 1 hr. Samples were then boiled for 5 mins and centrifuged at 13,000 219 g for 5 mins at room temperature (27). The supernatant was removed and glycogen was 220 measured using a Glycogen Assay Kit (Sigma-Aldrich) as per the manufacturer's protocol. 221
Background glucose levels were subtracted from glycogen measurements and samples were 222 normalized to total protein concentrations. Measurements were performed in duplicate. 223
224
Oxygen Consumption Rate and Extracellular Acidification Rate Measurements 225 E10.5 and E11.5 mouse hearts were isolated under aseptic conditions and cultured in 226 Dulbecco's modified eagle medium containing 10% fetal bovine serum (Hyclone Labs) that had 227 been charcoal-stripped to remove catecholamine and steroid hormones (41). The media was 228 additionally supplemented with penicillin G (100,000 U/L) and streptomycin (100 mg/L). Hearts 229 were cultured in a Seahorse Biosciences XF24 Islet Capture Microplate with mesh grids placed 230 on top of the specimen to prevent it from floating and from probe interference. Basal OCR and 231 ECAR were simultaneously measured at 10min intervals over a period of 2 hrs using a 232
Seahorse XF e Biosciences system. Rotenone (5 µM) and antimycin A (20 µM) were 233 simultaneously added (61) to block mitochondrial electron transport. 234
235
Gene Expression 236
RNA was isolated from flash-frozen embryonic hearts using TRIzol reagent, and converted to 237 cDNA using High Capacity cDNA Reverse Transcription Kit (Invitrogen). Real-time PCR was 238 performed using SYBR Green Fast reagent in an AB7500 machine (Applied Biosystems). 239 
Transmission Electron Microscopy 256
Briefly, isolated embryonic hearts were placed in Karnovsky's fixative (2% paraformaldehyde, 257 2.5% glutaraldehyde and 0.1 M sodium cacodylate, pH 7.3) for 1 hour. Samples were then 258 rinsed in 0.1 M sodium cacodylate with 3 µM CaCl 2 (pH 7.3), and post-fixed in a 1% osmium 259 tetroxide, 0.8% potassium ferrocyanide and 3 µM CaCl 2 solution. Samples were stained en bloc 260 with 2% uranyl acetate and dehydrated in graded ethanol solutions. Samples were embedded 261 in Durcupan, and sections were cut at 80 nm using a Leica UTC Ultramicrotome and diamond 262 knife, and then mounted on copper grids. Thin sections were stained with routine TEM double 263 stain: 4 mins in 4% uranyl acetate then 4-mins in Reynolds Lead Citrate. Thin sections were 264 examined using an FEI 268D TEM at 50Kv, and images recorded using an AMT XR-60 digital 265 camera. Mitochondrial morphometric and glycogen analyses were performed with ImageJ 266 software (NIH). 267
268
Oil Red O Staining 269
Oil Red O (5 mg/mL in isopropanol) stock stain was diluted to the working solution (60 percent 270 stock in distilled water), and used to stain for lipid droplets, as previously described (47). 271
Embryos were immediately placed in 2% fresh paraformaldehyde overnight and moved to 30% 272 sucrose and 0.02% sodium azide at 4ºC for storage. Frozen sections were made on a Leica 273 CM1850 cryostat at 12 µm thick at -20ºC. Briefly, the slides were air-dried, fixed in formalin, 274
and washed with running tap water for 1 min. They were then rinsed with 60% isopropanol, 275 stained with freshly prepared Oil Red O working solution for 15 mins. The staining solution was 276 then removed and the samples were rinsed with 60% isopropanol, rinsed further with distilled 277 water, and mounted using Vectashield mounting medium (Vector Labs). Digital micrographs 278 were obtained using a Leica DM2000 microscope, and images were analyzed for lipid droplets 279 using ImageJ software (NIH). 280
281
Free Fatty Acid Quantification 282
Fatty Acids were measured using the Free Fatty Acid Quantification Colorimetric/Fluorometric 283 Kit (Biovision) according to the manufacturer's instructions. Briefly, flash-frozen embryos were 284 homogenized for 30 sec then centrifuged at 12,000 g for 1 min. 100 µL 1% Triton-X 100 in 285 chloroform was added to the supernatant. Samples were centrifuged at 12,000 g for 10 mins 286 and the lower phase was transferred and allowed to air dry, pellets were then resuspended in 287 fatty acid buffer. Fluorescence readings were performed using an Envision Multilabel plate 288 reader (Perkin Elmer) (Excitation: 535nm and Emission: 590 nm). Known concentrations of 289 palmitic acid were used to generate a standard curve for this assay, and all samples were 290 measured in duplicate. 291
292
JC-1 dye 293
Myocytes were isolated and cultured on coverglass (for microscopy) or 48-well plates (for flow 294 cytometry) as described previously (38). Cardiomyocytes were cultured for 48 hours before 295 staining with JC-1 dye (5 µg/ml; Invitrogen) for 20 mins. The dye was washed with PBS and 296 samples were either viewed using a Perkin Elmer Spinning Disk confocal microscope or 297 quantified using a BDFacs Canto flow cytometer (BD Biosciences, Inc.). Gates were set with 298 unstained cells and carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP, 50 µM) 299 treated controls and quantified emission filters appropriate for Alexa Fluor® 488 nm and R-300 phycoerythrin. Data were analyzed using FCSExpress software (DeNovo). 
ATP is depleted in adrenergic-deficient embryos 311
To determine if adrenergic deficiency affects embryonic metabolism, we measured ATP and 312 as "adrenergic-competent". Dbh -/-mice fail to produce NE or EPI, and most will succumb to 317 heart failure and embryonic lethality between E10.5-E15.5 (54) unless rescued by maternal 318 supplementation of alternative catecholamine substrates (54) or β-adrenergic agonists, such as 319 isoproterenol (ISO) (55). 320 321 ATP concentrations were significantly decreased in adrenergic-deficient embryos as early as 322 E10.5, and declined precipitously by E11.5 ( Figure 1A ). Conversely, ADP concentrations 323 increased over the same time period in the Dbh -/-group relative to controls ( Figure 1B ). 324
ADP concentrations in adrenergic-competent (Dbh
Notably, both ATP and ADP concentrations were unchanged at E9.5 relative to adrenergic-325 competent controls ( Figure 1A , 1B). Steady-state ATP, ADP, and ATP/ADP values, generated 326 from known ATP and ADP standard curve concentrations, are shown in Table I for adrenergic-327 competent and deficient embryos. 328 329 ATP/ADP ratios were virtually identical in adrenergic-competent and deficient embryos at E9.5, 330 but then diverged dramatically over the next two days. In control embryos, the ATP/ADP ratio 331 steadily increased over this time period, but in Dbh -/-embryos, this ratio dropped by 50% at 332 E10.5 and by >95% (~48-fold reduction) at E11.5 ( Figure 1C ). It is important to note that all 333 embryos collected for these analyses appeared healthy and viable, as described in the 334 Materials and Methods section. Despite their outward appearance, however, Dbh -/-embryos 335 exhibited an ATP/ADP energy deficit beginning around E10.5 that rapidly became much more 336 severe by E11.5. 337
338
To determine if the observed energy depletion was due to the absence of β-adrenergic 339 stimulation, we provided ISO in the maternal drinking water to rescue the phenotype. When the 340 experiment was repeated under these conditions, the ATP deficits disappeared ( Figure 1D) . 341
We observed a 1.8-fold increase in ATP concentrations at E10.5 and a 4.5-fold increase in 342 E11.5 Dbh -/-ATP concentrations after ISO treatment compared to those observed without the 343 addition of ISO. These results demonstrate that β-adrenergic stimulation was effective at 344 preventing the energy loss resulting from adrenergic deficiency in developing mouse embryos. 345
346
Conversely, we applied the non-selective -adrenergic receptor antagonist, timolol (1 mg/ml) in 347 the maternal drinking water to determine if blockade of -receptors would influence ATP 348 concentrations in control (adrenergic-competent) embryos. E11.5 embryos from dams that 349 received timolol contained significantly less (~22% reduction, p<0.01, n=16 for no drug controls, 350 n=14 for timolol-treated group) ATP compared to age-matched controls that did not receive 351 timolol ( Figure 1E ). Taken together, these results suggest that adrenergic stimulation of -352 receptors is important for maintaining embryonic ATP concentrations. 353
354
We noticed, however, that while timolol was clearly effective at lowering ATP levels relative to 355 controls during this period of development ( Figure 1E ), there was a greater decrease in ATP 356 concentrations in the Dbh -/-age-matched embryos (compare panels A and E for E11.5, Figure  357 1). There are a number of possible explanations for this finding, including a potential role for -358 adrenergic receptors in regulating embryonic energy metabolism. To test this, we applied the -359 adrenergic receptor agonist, l-phenylephrine, in the maternal drinking water beginning at E8.5, 360 and again collected embryos at E11.5 to assess ATP concentrations. Remarkably, adrenergic-361 deficient embryos obtained from dams that received l-phenylephrine had significantly higher 362 concentrations of ATP than adrenergic-deficient embryos from dams that did not receive any 363 drug treatment as assessed by one-way ANOVA ( Figure 1F ). The recovery was not complete, 364 but nevertheless achieved 50-60% of the ATP levels observed in controls. These results 365 strongly suggest that embryonic ATP concentrations are positively regulated through -as well 366
as -adrenergic receptor stimulation. 367 368
Influence of adrenergic hormones on embryonic carbohydrate and lipid metabolism 369
Carbohydrate metabolism is the principal source of energy for the developing heart prior to birth, 370 though lipid utilization by the heart also begins during the embryonic period as the heart gains 371 oxidative metabolic capability (3, 17, 23, 48, 59 ). To determine if key carbohydrate metabolites 372 were altered in adrenergic-deficient embryos, we measured glucose, glycogen, and lactate 373 concentrations in embryos isolated at E10.5 and E11.5 (Table II) . No significant differences 374 were observed in the concentrations of these carbohydrate metabolites at these ages. 375
However, lactate concentrations appeared slightly elevated, on average, in adrenergic-deficient 376 embryos at both E10.5 and E11.5, but these differences were also not statistically significant. 377
Glycogen concentrations trended lower in the deficient group, but the results were variable and 378 again not found to be significantly different. The biochemical results for glycogen were 379 corroborated by image analysis of glycogen granules from transmission electron microscopy 380 (TEM) micrographs, which showed a similar insignificant downward trend in glycogen granules 381 at E11.5 for the adrenergic-deficient group (Table II) . We also measured free fatty acid 382 concentrations and lipid droplets, but found no significant differences in these either, though 383 there was a downward trend in the deficient group for lipid droplets, which were predominantly 384 located in the liver at these stages of development. Despite these trends, steady-state levels of 385 free fatty acids as well as glucose, glycogen, and lactate were relatively unchanged (no 386 significant differences) in adrenergic-deficient embryos compared to age-matched littermate 387 controls at E10.5 and E11.5. 388
389
When we examined the rate of glycolysis, however, significant differences were observed. To 390 perform these measurements, we isolated and cultured whole beating hearts from E10.5-E11.5 391
Dbh
-/-and littermate controls and recorded the extracellular acidification rate (ECAR) at various 392 intervals over a 40-min period. At E10.5, there was little difference in ECAR from adrenergic-393 deficient and control samples over the entire 40-mins (Figure 2A ). At E11.5, however, 394 adrenergic-deficient and control ECARs were similar initially, but began to decline in the 395 adrenergic-deficient group after about 10-mins and continued to decline further over the next 396
30-mins such that it was less than half the initial rate by 40-mins ( Figure 2B ). This decline was 397
prevented by the addition of ISO in the maternal drinking water ( Figure 2C ). These results 398 suggest that glycolytic rate was compromised in adrenergic-deficient hearts by E11.5. 399 400
Oxygen consumption rate (OCR) decrease due to absence of β-adrenergic stimulation 401
Mitochondria play an increasingly important role in the heart at these early embryonic stages of 402 development. OCR measurements from isolated embryonic hearts can be used to estimate 403 mitochondrial respiration. Prior to OCR measurements, beating rates were taken in isolated 404 embryonic hearts to verify the viability of tissue collected. Similar beating rates were observed 405 in the adrenergic-competent and deficient samples at both ages (Table III) . To confirm the OCR 406 was from mitochondrial function, we administered rotenone (5 µM) and antimycin A (20 µM) to 407 control hearts to block complexes I and III, respectively. This treatment significantly decreased 408 the overall OCR by 50-60% ( Figure 3A and 3B) , indicating that at least half of the observed 409 OCR in E10.5-E11.5 mouse hearts was dependent on mitochondrial respiration. The remaining 410 portion likely reflects other oxidation reactions within the cells, as has been commonly observed 411 in other systems (9, 28, 60) . 412
413
We found that adrenergic-deficient hearts had lower rates of oxygen consumption, on average, 414 compared with littermate controls (Figure 3C and D) . Nevertheless, OCR increased similarly in 415 adrenergic-deficient and competent hearts between E10.5 and E11.5 (compare panels C & D, 416 Figure 3 ), but the adrenergic-deficient OCR continued to lag significantly below the control 417 group through E11.5. As indicated above, the hearts appeared similar and were beating 418 spontaneously at comparable slow but steady rates in both adrenergic-deficient and competent 419 hearts during the ex vivo culture period (Table III) . Thus, despite the lack of any clear 420 differences in outward appearance or behavior, adrenergic-deficient hearts consumed oxygen at 421 significantly lower rates than control hearts. To verify this effect was due to the absence of 422 adrenergic hormones, we provided ISO in the maternal drinking water, which restored OCR to 423 control levels in adrenergic-deficient hearts (Figure 3 
panels E & F). Acute administration of 424
ISO to the isolated heart in culture, however, did not result in any significant changes in OCR 425 over a 1-hr recording period (not shown). These results suggest that longer term treatment with 426 ISO in vivo is needed to effectively prevent the decline in OCR observed in adrenergic-deficient 427
hearts. 428 429
Mitochondrial biogenesis not affected by the loss of adrenergic-hormones 430
In theory, the lowered OCR and ATP/ADP ratio could be due to fewer mitochondria resulting 431 from compromised mitochondrial biogenesis in adrenergic-deficient hearts. To test this 432 hypothesis, we measured expression of key mitochondrial biogenesis genes in isolated hearts, 433 but no significant alterations in mRNA for Pgc-1α (p=0.58), Tfam (p=0.47), and Sirt1 (p=0.65) 434
were found in E10.5 isolated hearts when normalized to the housekeeping gene β-actin (Figure  435 4A). Similar results were found at E11.5. We also measured mitochondrial DNA (mtDNA) 436 content present in adrenergic-deficient and control hearts, but no significant differences were 437 observed ( Figure 4B ). There was an apparent increase in mtDNA at E10.5, which could be 438 related to the similar upward trend seen in Pgc-1α from this group (compare Figure 4A and 4B) , 439 but neither of these differences were significant, and both trends had disappeared by E11.5. 440
These results suggest that mitochondrial biogenesis is not likely a limiting factor in adrenergic-441 deficient embryos at these early stages. 442 443
Adrenergic-deficient myocytes have intact mitochondrial membranes 444
The decreased OCR in adrenergic-deficient hearts suggests that mitochondrial function may be 445 laser-scanning confocal fluorescence microscopy to assess mitochondrial membrane potential 453 integrity in cardiomyocytes isolated from E10.5 and E11.5 adrenergic-competent and deficient 454 hearts. Flow cytometry for red (aggregates) and green (monomers) showed no difference 455 between adrenergic-deficient and control samples at E10.5 ( Figure 5A ) or E11.5 ( Figure 5C ). 456
Quantification of the stained primary cardiomyocyte culture showed a red to green ratio of 3.4 ± 457 0.7; n=9 in the E10.5 deficient samples and 3.1 ± 0.6; n=9 in controls ( Figure 5B ). Similar 458 results were observed in the E11.5 primary cardiomyocyte cultures with the red to green ratio of 459 3.4 ± 1.3; n=4 in the deficient group and 2.5 ± 0.8; n=4 in the control group ( Figure 5D) . 460
Representative mitochondrial staining with JC-1 is shown in Figure 5E for adrenergic-competent 461 and deficient myocytes isolated from E11.5 hearts. Despite the fact there were no significant 462 differences in the ratio of red/green staining in these specimens, the mitochondrial staining 463 pattern in the adrenergic-deficient group appeared to be less densely clustered and less well-464 organized within myocytes than those typically found in age-matched adrenergic-competent 465 littermates, indicating there may be structural abnormalities in mitochondria from adrenergic-466 deficient embryos. At this resolution, however, it was difficult to determine if there were truly 467 structural anomalies in the mitochondria, so we employed transmission electron microscopy 468 (TEM) for these evaluations as described below. 469
470
Mitochondrial morphology altered in adrenergic-deficient hearts 471
To obtain a detailed view and assessment of mitochondrial structure in adrenergic-deficient and 472 control embryonic hearts, we analyzed cardiac tissue specimens using transmission electron 473 microscopy (TEM). Our results show that mitochondria within E10.5 adrenergic-deficient 474 myocardium were enlarged and appeared swollen relative to adrenergic-competent controls 475 Figure 6H ). Adrenergic-deficient myocyte samples had fewer mitochondria per 482 micrograph compared to adrenergic-competent hearts at E11.5, a trend that was evident at 483 E10.5, though the numbers were more similar to control values at that age (Table IV) . 484
Mitochondrial length was significantly increased at E10.5 (p<0.05) and at E11.5 (p<0.0001) by 485 nearly 30% in the adrenergic-deficient samples versus controls (Table IV) . Mitochondrial 486 surface area was also significantly increased at E10.5 (p<0.05) and at E11.5 (p<0.001) in 487 adrenergic-deficient myocytes compared to controls (Table IV) . These results clearly show that 488 mitochondrial structure was significantly altered in adrenergic-deficient embryos. On average, 489 the mitochondria were longer, had greater surface area, and displayed more abnormal shapes 490 such as branch points, curvatures, and budding bulges in their membranes compared with their 491 control counterparts. 492
493
DISCUSSION 494 495
Anaerobic glycolysis is the predominant mode of metabolism of the heart during early 496 embryonic development, but aerobic mitochondrial metabolism becomes an increasingly 497 important and essential mode of ATP production at late embryonic to early fetal stages of 498 development (7, 17, 23, 48) . For example, classic studies showed that isolated embryonic rat 499 hearts utilized glycolytic mechanisms through E11; however, glycolysis was not sufficient to 500 maintain maximal heart rates at E12 or E13 (17). Further, energy metabolism was unaffected 501 by the presence of oxygen at E11 in the rat, but was significantly and progressively elevated by 502 oxygen in E12 and E13 hearts. This embryonic-shift in metabolic capability between E11-E12 in 503 the rat roughly corresponds to the end of the organogenesis period of embryonic development 504 and the beginning of fetal development. In the mouse, the equivalent stages of development 505 are approximately E9.5-E10.5 (53). It is during this late embryonic period when metabolic 506 deficiencies first become apparent in adrenergic-deficient (Dbh -/-) mouse embryos. 507 508 At E9.5, there were no discernible differences in ATP or ADP concentrations in adrenergic-509 deficient and control embryos, but ATP/ADP ratios began to decline at E10.5 and much more 510 dramatically so at E11.5 in adrenergic-deficient embryos. This was mediated, in part, through β-511 adrenergic receptors since administration of the β-agonist, isoproterenol, was able to "rescue" 512 the loss of ATP observed in Dbh -/-embryos. Further, administration of the β-antagonist, timolol, 513 induced significant decreases in ATP concentrations in adrenergic-competent control embryos. 514
These results support a role for β-adrenergic receptor stimulation in regulation of ATP. 515
516
There also appears to be a role for α-adrenergic receptor involvement since the α-agonist, 517 phenylephrine, was also able to "rescue" ATP concentrations in adrenergic-deficient embryos. 518
In both rescue experiments, ATP depletion was partially rescued by either α-or β-agonists, 519 suggesting that both pathways likely contribute to adrenergic influence of ATP regulation in the 520 developing embryo. It should be noted, however, that further work is needed to fully elucidate 521 the molecular signaling pathways leading from receptor stimulation to regulation of ATP 522 homeostasis. One must be cautious interpreting pharmacological data since partial effects 523 could be attributed to a number of different factors including drug dosage, secondary or other 524 indirect effects, drug distribution/penetrance in the embryo due to placental barrier, and other 525 factors that may not be readily apparent. These caveats notwithstanding, the results of our 526 pharmacological experiments are consistent with those observed in the genetic knockout 527 experiments described in this study. In both cases, the results showed that adrenergic 528 stimulation is needed to maintain embryonic ATP concentrations during critical early stages of 529
development. 530 531
ATP is generated by glycolysis and mitochondrial oxidative phosphorylation. Our results 532 suggest that that the decline in ATP/ADP cannot be fully ascribed to glycolysis since no 533 significant differences were observed in key glycolytic metabolites including glycogen, glucose, 534 and lactate at E10.5 or E11.5. In addition, ECAR was virtually identical at E10.5 in adrenergic-535 deficient and control embryos. By E11.5, however, ECAR was selectively decreased in the 536 adrenergic-deficient group, indicating that glycolytic rate may have been compromised. The 537 decline was not apparent immediately, but developed over 15-30 mins, and was completely 538 prevented by supplying the β-agonist, isoproterenol in the maternal drinking water. These 539 results suggest that adrenergic stimulation is needed to maintain glycolytic rates after E10.5 in 540 mouse embryos. 541
542
As we have shown, OCR was also significantly decreased in adrenergic-deficient hearts at 543 E10.5 and E11.5 relative to littermate controls. These results suggest that aerobic metabolism 544 was likely compromised in these embryos. It appeared that basal OCR in adrenergic-deficient 545 hearts lagged about a day behind adrenergic-competent hearts, and was only about 50% of 546 control levels at E10.5 and E11.5. These effects were extinguished by supplying isoproterenol 547 in the maternal drinking water, thereby indicating the absence of β-adrenergic stimulation was 548 responsible for the declining OCRs in Dbh -/-embryos. These results suggest that oxidative 549 metabolism may have been impaired in adrenergic-deficient embryos. 550
551
Since oxidative phosphorylation occurs primarily in mitochondria, we examined mitochondrial 552 ultrastructure directly in the embryonic heart using TEM, and found that it was significantly 553 altered in adrenergic-deficient embryos. TEM analyses showed that mitochondria were 554 enlarged and more frequently displayed branching or budding membranes in adrenergic-555 deficient hearts at E10.5 and E11.5. Despite the abnormal mitochondrial morphology in these 556 hearts, the membranes appeared to be intact with well-formed cristae. Further, no significant 557 alterations in red/green fluorescence ratios were observed following application of the 558 mitochondrial membrane potential-sensitive dye, JC-1, in adrenergic-deficient hearts compared 559 with controls. These findings suggest that although the mitochondria were larger and 560 abnormally shaped, the observed structural changes may represent compensatory mechanisms 561 to increase ATP production in energy-starved Dbh -/-hearts (25, 39). Indeed, enlarged 562 mitochondria have been associated with enhanced metabolic output while smaller fragmented 563 mitochondria have generally been associated with decreased metabolic output (31, 44, 52). In 564 the present study, however, we observed enlarged mitochondria with apparent decreased 565 metabolic output. This phenomenon of elongated mitochondria with diminished function has 566 been demonstrated previously in other models of mitochondrial dysfunction (4, 11, 14, 40) . 567
568
We tested the hypothesis that Dbh -/-embryos may be starved for substrate metabolites, but little 569 change was observed in key carbohydrate or lipid substrates. This result was not entirely 570 unexpected since glucose is known to pass freely from maternal blood supply to the embryo 571 (51). These results suggest that metabolic substrates were not depleted in adrenergic-deficient 572
embryos. 573 574
The pathophysiology of adult heart failure is commonly characterized by mitochondrial 575 dysfunction, indicated by decreased energy levels (30, 56, 57) . In the Dbh -/-embryos, however, 576 signs of energy starvation were seen before any outward precursor of heart failure. Indeed, 577 metabolic deficiencies were observed in Dbh -/-embryos that were otherwise phenotypically 578 indistinguishable from adrenergic-competent controls at the time of isolation in terms of size, 579 morphology, color, texture, and cardiac beating activity. These results suggest that metabolic 580 defects likely contribute to the subsequent heart failure and embryonic lethality in this model. 581
The depletion of ATP concentrations could be largely prevented by maternal administration of 582 either an α-adrenergic agonist (l-phenylephrine) or a β-adrenergic agonist (ISO), suggests that 583 both of the major adrenergic signal transduction pathways play important roles to ensure 584 adequate supplies of ATP available for embryonic/fetal growth and development (55). 585
586
In summary, we have shown that adrenergic hormones fulfill a critical developmental role by 587 providing the growing embryo with sufficient chemical energy in the form of ATP to enable 588 successful transition from embryonic to fetal stages. Further, our results demonstrate that 589 adrenergic hormones are necessary to maintain sufficient ATP/ADP, ECAR, and OCR during 590 late periods of embryonic development in preparation for the transition to the fetal period. The 591 discovery of these influential regulatory connections between adrenergic hormones and 592 embryonic energy metabolism opens new paths for the study of cardiovascular development 593 that could give rise to novel therapeutic targets and strategies for treating congenital heart 594 defects (13, 32) as well as adult forms of heart disease. 595 596 597
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